U. Chakravarthy UK

15:15 Welcome

M.A. Zouache USA

15:17 Protective CFH-CFHR5 haplotypes mitigate risk for age-related macular degeneration associated with the ARMS2/HTRA1 locus.

F. G. Holz GERMANY

15:23 Faricimab in Neovascular Age-Related Macular Degeneration: Year 2 Efficacy, Safety and Durability Results From the Phase 3 TENAYA and LUCERNE Trials

M.S. Figueroa SPAIN

15:29 Key Clinical Pearls for Evaluating Surgical Candidates, and Patient Preference, for the Port Delivery System With Ranibizumab

U. Chakravarthy UK

15:35 Central Subfield Thickness Fluctuations and Their Impact on Vision Outcomes Over 96 Weeks in the Archway Trial of the Port Delivery System With Ranibizumab (PDS)

A. Khanani USA

15:41 Key Pearls of the Refill-Exchange Procedure for the Port Delivery System With Ranibizumab

G. Boscia ITALY

15:47 Macular thickness and visual acuity are characterized by a quadratic nonlinear relation in previously treated neovascular AMD eyes: retinal thickness deviation values may better predict visual function in these eyes

M. Airaldi ITALY

15:53 Differences in long-term progression of atrophy between neovascular and non-neovascular age-related macular degeneration

V. Sarao ITALY

15:59 Progression of geographic atrophy in the course of treatment of neovascular age-related macular degeneration with anti-vascular endothelial growth factor agents

M.L. Martínez Sánchez SPAIN

16:05 COVID-19, the pandemic that held Europe to a standstill and its impact in patients affected by neovascular age related macular degeneration (nAMD). The nAMD EUROCOVCAT study.

All Faculty

16:11 Discussion